Literature DB >> 11139437

Alteration of the [Ca(2+)](i)-force relationship during the vasorelaxation induced by a Ca(2+) channel blocker SR33805 in the porcine coronary artery.

S Ieiri1, K Hirano, J Nishimura, S Suita, H Kanaide.   

Abstract

The mechanism of vasorelaxation induced by SR33805 was investigated by simultaneously monitoring the cytosolic Ca(2+) concentration ([Ca(2+)](i)) and force, and by determining level of myosin light chain (MLC) phosphorylation in the medial strip of the porcine coronary artery. SR33805 inhibited the sustained increases in [Ca(2+)](i) and force (IC(50); 3.2+/-1.0 and 49.4+/-27.5 nM, respectively) induced by 118 mM K(+)-depolarization. There was about a 10 fold difference in the inhibitory potency between [Ca(2+)](i) and force. SR33805 completely inhibited the [Ca(2+)](i) elevation induced by a thromboxane A(2) analogue, U46619 and histamine, at concentrations (1 microM) higher than those required for the complete inhibition of K(+)-depolarization induced [Ca(2+)](i) elevation. SR33805 had no effect on the [Ca(2+)](i) elevation induced by histamine or caffeine in the absence of extracellular Ca(2+). SR33805 caused a leftward shift of the [Ca(2+)](i)-force relationship of the contraction induced by cumulative application of extracellular Ca(2+) during 118 mM K(+)-depolarization. The relationship between [Ca(2+)](i) and MLC phosphorylation also shifted to the left by SR33805, while the relationship between MLC phosphorylation and force remained unaffected. In conclusion, SR33805 caused an apparent leftward shift of the [Ca(2+)](i)-force relationship, accompanied by a greater degree of MLC phosphorylation for a given level of [Ca(2+)](i). The mechanism of this leftward shift, however, still remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11139437      PMCID: PMC1572486          DOI: 10.1038/sj.bjp.0703721

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  34 in total

1.  U46619, a thromboxane A2 agonist, inhibits KCa channel activity from pig coronary artery.

Authors:  F S Scornik; L Toro
Journal:  Am J Physiol       Date:  1992-03

2.  Ca2+ channel activation and membrane depolarization mediated by Cl- channels in response to noradrenaline in vascular myocytes.

Authors:  P Pacaud; G Loirand; A Baron; C Mironneau; J Mironneau
Journal:  Br J Pharmacol       Date:  1991-12       Impact factor: 8.739

3.  Angiotensin II blocks ATP-sensitive K+ channels in porcine coronary artery smooth muscle cells.

Authors:  Y Miyoshi; Y Nakaya
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

Review 4.  Signal transduction and regulation in smooth muscle.

Authors:  A P Somlyo; A V Somlyo
Journal:  Nature       Date:  1994-11-17       Impact factor: 49.962

5.  Effects of okadaic acid on cytosolic calcium concentrations and on contractions of the porcine coronary artery.

Authors:  K Hirano; H Kanaide; M Nakamura
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

6.  Effects of diltiazem on calcium concentrations in the cytosol and on force of contractions in porcine coronary arterial strips.

Authors:  K Hirano; H Kanaide; S Abe; M Nakamura
Journal:  Br J Pharmacol       Date:  1990-10       Impact factor: 8.739

7.  In vitro characterization of a novel Ca2+ entry blocker: SR 33805.

Authors:  P Chatelain; M Clinet; P Polster; B Christophe; A S Manning
Journal:  Eur J Pharmacol       Date:  1993-08-15       Impact factor: 4.432

Review 8.  Pharmacology of bepridil.

Authors:  A Gill; S F Flaim; B P Damiano; S P Sit; M D Brannan
Journal:  Am J Cardiol       Date:  1992-04-09       Impact factor: 2.778

9.  Characterization of the binding of [3H]SR 33805 to the slow Ca2+ channel in rat heart sarcolemmal membrane.

Authors:  P Chatelain; P Dewinkeleer; P Beaufort; L Meysmans; M Clinet
Journal:  Eur J Pharmacol       Date:  1994-04-15       Impact factor: 4.432

10.  The long-term inhibitory effect of a Ca2+ channel blocker, nisoldipine, on cytosolic Ca2+ and contraction in vascular smooth muscle.

Authors:  B K Kim; M Mitsui; H Karaki
Journal:  Eur J Pharmacol       Date:  1992-11-17       Impact factor: 4.432

View more
  2 in total

1.  Beneficial effects of SR33805 in failing myocardium.

Authors:  Younss Ait Mou; Attila Toth; Cécile Cassan; Daniel Czuriga; Pieter P de Tombe; Zoltan Papp; Alain Lacampagne; Olivier Cazorla
Journal:  Cardiovasc Res       Date:  2011-04-04       Impact factor: 10.787

2.  SR33805, a Ca2+ antagonist with length-dependent Ca2+ -sensitizing properties in cardiac myocytes.

Authors:  Olivier Cazorla; Alain Lacampagne; Jeremy Fauconnier; Guy Vassort
Journal:  Br J Pharmacol       Date:  2003-05       Impact factor: 8.739

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.